Locations:
Search
Inclusion of genomic profiling and risk factors recommended for treatment planning
Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer
Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin
Treatment assigned FDA review date in June 2025
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit
Cleveland Clinic, the University of Minnesota and University of Cambridge receive $1M grant to develop point-of-care biosensor for early detection and treatment personalization
Long-acting antiemetics and high-dose steroids key to minimizing acute nausea
Greater awareness among young patients is needed
Neoadjuvant immunotherapy improves outcomes
Use of GLP-1s and improving cardiovascular health lowers risk of hematologic malignancies
Advertisement
Advertisement